Endoleak

内漏
  • 文章类型: Journal Article
    在主动脉动脉瘤的血管内主动脉修复(EVAR)后的随访期间,可能会出现髂内动脉(IIA)引起的晚期II型内漏(T2ELs),如果证实动脉瘤囊扩大,则可能需要栓塞。当IIA口由于广泛的髂关节疾病而被覆盖时,访问选项可能具有挑战性。近年来报道了不同的治疗方案,必须根据每种情况的特点,仔细选择最好的。本研究报告了一种简单且可重复的无鞘经皮臀上动脉(SGA)通道,并根据对该主题的现有文献的回顾进行了讨论。
    Late type II endoleaks (T2ELs) arising from the internal iliac artery (IIA) may present during follow-up after endovascular aortic repair (EVAR) of aortoiliac aneurysm and may warrant embolization if enlargement of the aneurysmal sac is demonstrated. When coverage of the IIA ostium has been made due to extensive iliac disease, access options can be challenging. Different treatment options have been reported over recent years, and a careful selection of the best one must be made based on the characteristics of each case. The present study reports a simple and reproducible sheathless percutaneous superior gluteal artery (SGA) access and provides a discussion based on a review of the existing literature on this topic.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    胸血管内动脉瘤修复术(TEVAR)已取代开放式手术修复术,成为几种主动脉疾病的首选治疗方法。尽管发病率和死亡率较低,可能发生几种TEVAR相关并发症,其中一些可能需要手术或血管内再介入治疗.本文回顾了TEVAR手术的常见和罕见并发症,重点是横断面成像可识别的并发症和术前计划的潜在陷阱。
    Thoracic endovascular aneurysm repair (TEVAR) has replaced open surgical repair as the treatment of choice for several aortic conditions. Despite its lower morbidity and mortality, several TEVAR-related complications can occur and some of which may necessitate surgical or endovascular re-intervention. The current article reviews common and rare complications of TEVAR procedure with emphasis on complications identifiable on cross-sectional imaging and potential pitfalls of pre-procedural planning.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景/目的:本系统综述旨在探讨腹腔镜肠系膜下动脉结扎(IMA)的有效性和安全性,这是解决腔内主动脉瘤修复(EVAR)后II型内漏的新兴趋势。方法:在包括Medline在内的多个数据库中进行了全面的文献检索,Scopus,和Cochrane中央控制试验登记册,遵守PRISMA准则。搜索的重点是报道IMA腹腔镜结扎治疗EVAR后II型内漏的文章。提取有关研究特征的数据,患者人口统计学,技术成功率,术后结果,和后续结果。结果:我们的分析包括十项病例研究和两项回顾性队列研究,包括2000年至2023年期间接受了IMA腹腔镜结扎术的26例患者。该队列的平均年龄为72.3岁,男性占主导地位(92.3%)。介入时的平均AAA直径为69.7mm。该技术具有92.3%的高技术成功率,平均手术时间为118.4分钟,失血最少。平均随访时间为19.9个月,73%的患者经历了动脉瘤囊的消退,在随访期间没有IMA相关的II型内漏的报告。结论:IMA腹腔镜结扎术治疗EVAR后II型内漏是一种有前途的方法,具有较高的技术成功率和良好的术后结局的微创替代方案。尽管它有潜在的优势,包括减少造影剂的使用和辐射暴露,它的应用仍然限于专业中心。研究结果表明,需要在更大的前瞻性研究中进行进一步研究,以验证该程序的有效性,并有可能扩大其临床应用范围。
    Background/Objectives: this systematic review aims to explore the efficacy and safety of the laparoscopic ligation of the inferior mesenteric artery (IMA) as an emerging trend for addressing a type II endoleak following endovascular aortic aneurysm repair (EVAR). Methods: A comprehensive literature search was conducted across several databases including Medline, Scopus, and the Cochrane Central Register of Controlled Trials, adhering to the PRISMA guidelines. The search focused on articles reporting on the laparoscopic ligation of the IMA for the treatment of a type II endoleak post-EVAR. Data were extracted regarding study characteristics, patient demographics, technical success rates, postoperative outcomes, and follow-up results. Results: Our analysis included ten case studies and two retrospective cohort studies, comprising a total of 26 patients who underwent a laparoscopic ligation of the IMA between 2000 and 2023. The mean age of the cohort was 72.3 years, with a male predominance (92.3%). The mean AAA diameter at the time of intervention was 69.7 mm. The technique demonstrated a high technical success rate of 92.3%, with a mean procedure time of 118.4 min and minimal blood loss. The average follow-up duration was 19.9 months, with 73% of patients experiencing regression of the aneurysmal sac, and no reports of an IMA-related type II endoleak during the follow-up period. Conclusions: The laparoscopic ligation of the IMA for a type II endoleak following EVAR presents a promising, minimally invasive alternative with high technical success rates and favorable postoperative outcomes. Despite its potential advantages, including reduced contrast agent use and radiation exposure, its application remains limited to specialized centers. The findings suggest the need for further research in larger prospective studies to validate the effectiveness of this procedure and potentially broaden its clinical adoption.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    本系统综述旨在总结内锚的有效性和安全性,用于近端移植物的稳定装置,旨在防止血管内动脉瘤修复(EVAR)和胸部血管内动脉瘤修复(TEVAR)中的内漏和支架迁移。
    根据系统评价和荟萃分析(PRISMA)指南的首选报告项目进行系统评价和荟萃分析。检索截至2023年5月31日的文献,并从4个数据库中独立筛选。数据汇总用于荟萃分析。主要结果包括术中和随访内漏,支架迁移,和再干预率;囊消退;和30天全因死亡率。
    使用Heli-FxEndoAnchor系统的16项EVAR研究(n=1145)和6项TEVAR研究(n=163)来自2225条检索记录。对于EVAR患者(平均随访=11.9个月),内漏,移植物迁移,再干预率为3.97%(95%置信区间[CI]=0.36%-1.99%),0.004%(95%CI=0.00%-0.76%),和5.43%(95%CI=0.86%-12.54%),分别。原发性和修订EVAR的内漏率分别为0.16%(95%CI=0.00%-1.65%)和3.60%(95%CI=0.14%-9.72%),分别。文献中仅报道了4例30天死亡(n=4)。对于TEVAR患者,内漏,支架迁移,再干预率为7.4%(95%CI=0.03%-0.13%),0.2%(95%CI=0.00%-0.06%),和17.1%(95%CI=0.01%-0.45%),分别。30天死亡率为0.9%(95%CI=0%-0.12%)。
    EVAR和TEVAR中的Endobler固定在预防和治疗内漏和支架迁移方面是有效且安全的。EVAR的死亡率最低,而TEVAR的死亡率更高。
    结论:内漏,移植物迁移,并且很少使用内锚钉对EVAR和TEVAR进行再干预。EVAR死亡率较低。内锚的辅助部署是预防和治疗EVAR和TEVAR中的内漏和支架移位的有效且安全的手段。然而,需要长期疗效和安全性数据以及随机对照试验,才能在常规临床实践中明确推荐使用endanchor.
    UNASSIGNED: This systematic review aimed to summarize the effectiveness and safety of endoanchor, a stabilizing device for the proximal endograft designed to prevent endoleak and stent migration in endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR).
    UNASSIGNED: A systematic review and meta-analysis was conducted per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline. Literature up to May 31, 2023 was searched and independently screened from 4 databases. Data were pooled for meta-analysis. Primary outcomes included intraoperative and follow-up endoleak, stent migration, and reintervention rates; sac regression; and 30-day all-cause mortality.
    UNASSIGNED: Sixteen EVAR (n=1145) and 6 TEVAR studies (n=163) using the Heli-Fx EndoAnchor system were included from 2225 retrieved records. For EVAR patients (mean follow-up=11.9 months), the endoleak, graft migration, and reintervention rates were 3.97% (95% confidence interval [CI]=0.36%-1.99%), 0.004% (95% CI=0.00%-0.76%), and 5.43% (95% CI=0.86%-12.54%), respectively. The endoleak rates for primary and revision EVAR were 0.16% (95% CI=0.00%-1.65%) and 3.60% (95% CI=0.14%-9.72%), respectively. Only 4 cases of 30-day mortality (n=4) were reported in the literature. For TEVAR patients, the endoleak, stent migration, and reintervention rates were 7.4% (95% CI=0.03%-0.13%), 0.2% (95% CI=0.00%-0.06%), and 17.1% (95% CI=0.01%-0.45%), respectively. The 30-day mortality was 0.9% (95% CI=0%-0.12%).
    UNASSIGNED: Endoanchor fixation in EVAR and TEVAR is effective and safe in preventing and treating endoleak and stent migration. The mortality is minimal in EVAR but higher in TEVAR.
    CONCLUSIONS: Endoleak, graft migration, and reintervention in EVAR and TEVAR with endoanchor use were rare. Mortality in EVAR was low. The adjunctive deployment of endoanchors is an effective and safe means to prevent and treat endoleak and stent migration in EVAR and TEVAR. Yet, long-term efficacy and safety data and randomized controlled trials would be required to definitively recommend endoanchor use in routine clinical practice.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    :内皮张力是一种罕见的晚期并发症,其特征是腔内主动脉瘤修复术(EVAR)后囊大小增加而没有任何类型的内漏。由于它的稀有性,很少有研究证明了内毒素背后的机制和管理。在这项研究中,我们的目的是更好地了解单中心队列中内毒素的治疗和长期结局.
    :本研究旨在对2006年1月至2017年12月期间诊断为内毒素的患者进行回顾性审查。根据在诊断内毒素之前存在任何类型的内漏,将研究患者分为两组(原发性与继发性)。我们收集了与内毒素治疗相关的数据,术中发现,和长期结果。
    :在一个由15名诊断为EVAR后内阻的患者组成的队列中,八人被归类为初级内毒素(PE)组,没有先前的内漏,7人表现出继发性内毒素(SE)。在8名PE患者中,在6例患者中进行了以先发制人为目的的血管内介入治疗;然而,三个(50%)显示持续的囊扩张,并最终获得开放转换。总的来说,8例患者(5例PE和3例SE)进行了开放转换,和一个(12.5%)在手术发现期间出现未检测到的内漏。在3例没有手术死亡的患者中观察到术后发病率。
    :最初可以通过简单观察系列图像的变化来管理Endottension,以及抢先的血管内介入。然而,对于具有特定适应症(包括动脉瘤囊持续扩大)的患者,应考虑手术干预,存在的症状,怀疑有内漏的支架移植物迁移,和感染。
    UNASSIGNED: : Endotension is a rare late complication characterized by an increase in sac size without any type of endoleak following endovascular aortic aneurysm repair (EVAR). Due to its rarity, few studies have demonstrated the mechanism behind and the management of endotension. In this study, we aimed to better understand the treatment and the long-term outcome of endotension in a single-center cohort.
    UNASSIGNED: : This study was designed for a retrospective review of the patients diagnosed with endotension between January 2006 and December 2017. The study patients were categorized into two groups (primary versus secondary) based on the presence of any type of endoleak before the diagnosis of endotension. We collected data related to endotension treatment, intraoperative findings, and long-term outcomes.
    UNASSIGNED: : In a cohort of 15 patients diagnosed with endotension following EVAR, eight were classified into the primary endotension (PE) group without prior endoleak, and seven exhibited secondary endotension (SE). Among the eight PE patients, endovascular intervention for a preemptive purpose was conducted in six patients; however, three (50%) showed continuous sac expansion and finally received open conversion. Overall, eight patients (five in PE and three in SE) underwent open conversion, and one (12.5%) presented with an undetected endoleak during the operative findings. Postoperative morbidity was observed in three patients with no operative mortality.
    UNASSIGNED: : Endotension can be managed initially through simple observation for changes on serial images, along with preemptive endovascular intervention. However, surgical intervention should be considered for patients with specific indications including continuous aneurysm sac enlargement, presence of symptoms, suspicions of migration of stent-graft with endoleak, and infection.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Systematic Review
    目的:植入后综合征(PIS)是血管内主动脉修复(EVAR)后的早期全身炎症反应。患者的反应是可变的,PIS对结果的临床意义未知。本研究旨在评估发病率,PIS的危险因素和预后意义。
    方法:根据PubMed的PRISMA和Cochrane指南进行了系统的文献回顾和分析,Scopus,ClinicalTrials.gov和Cochrane中央对照试验登记册。纳入了关于肾下EVAR后PIS的合格英语研究,删除重复项之后。
    结果:筛选后,包括31项研究。共有2,847名患者接受了审查,平均年龄为70.7岁,其中2012年(90.4%)为男性,合并平均随访26.1个月.在25.3%的平均动脉瘤直径为56.4cm的病例中报告了PIS。1839年,794名患者(27.9%)使用聚酯(64.6%)使用了PTFE移植物。WBC,CRP,术后IL-6、IL-8和IL-10水平均显著升高。30天的结果包括I型内漏率为0.8%,II型内漏1.7%,再干预0.35%,死亡率0.25%。PIS患者(309例)与非PIS患者(691例)的亚组汇总分析显示,聚酯(642例),而不是PTFE(234)移植物,与较高的PIS率相关(94.8%与3.7%;p=0.0001),PIS组术前WBC计数均较高(7.61vs.6.76;p=0.04)和术后(15.0vs.9.8;p=0.0007),PIS组术后IL-6水平较高(98.6vs.25.2;p=0.02)。动脉瘤直径和动脉瘤囊内慢性或新血栓的数量未被确定为PIS的危险因素。PIS患者的汇总结果与无PIS显示30天死亡率显著较高(0.6%vs.0%;p=0.03)和主要不良心脏事件(5.8%vs.0.43%;p<0.0001)在再干预方面没有任何差异,30天I型或II型内漏。
    结论:本系统综述表明,与PTFE相比,聚酯移植物与PIS密切相关。有趣的是,本报告提示30日死亡率与主要不良心脏事件和PIS之间存在关联.鉴于这些临床后遗症,考虑在聚酯移植物上使用PTFE来减少PIS的发生率可能是改善总体结果的简单步骤。Further,探索与PIS相关的炎症介质与死亡率和心脏并发症之间的关系可能会导致对风险的更深入理解,最终减轻PIS患者的伤害。
    OBJECTIVE: Post implantation syndrome (PIS) is an early systemic inflammatory response following endovascular aortic repair (EVAR). The response is variable in patients and the clinical significance of PIS upon outcomes is unknown. This study aims to evaluate the incidence, risk factors, and prognostic implication of PIS.
    METHODS: Systematic literature review and analysis was performed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) and Cochrane guidelines of PubMed, Scopus, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials. Eligible English-language studies regarding PIS after infrarenal EVAR were included, after removing duplicates.
    RESULTS: After screening, 31 studies were included. A total of 2847 patients were reviewed, with mean age of 70.7 years, of which 2012 (90.4%) were male, with a pooled mean follow-up of 26.1 months. PIS was reported in 25.3% of cases, with mean aneurysm diameter of 56.4 cm. Polytetrafluoroethylene (PTFE) grafts were utilized in 794 patients (27.9%) with polyester in 1839 (64.6%). White blood cell count, C-reactive protein, interleukin (IL)-6, IL-8, and IL-10 levels were all significantly elevated postoperatively. Thirty-day outcomes included type I endoleak rate of 0.8%, type II endoleak rate of 1.7%, reintervention rate of 0.35%, and mortality rate of 0.25%. Subgroup pooled analysis of patients with PIS (n = 309) vs No-PIS (n = 691) revealed that polyester (n = 642), rather than PTFE (n = 234) grafts, were associated with a higher rate of PIS (94.8% vs 3.7%; P = .0001), White blood cell count was higher in the PIS group both preoperatively (7.61 vs 6.76 × 109/L; P = .04) and postoperatively (15.0 vs 9.8 × 109/L; P = .0007) and IL-6 levels were higher in the PIS group postoperatively (98.6 vs 25.2 pg/mL; P = .02). Aneurysm diameter and amount of chronic or new thrombus within the aneurysm sac was not identified as a risk factor for PIS. Pooled outcomes of patients with PIS vs No-PIS demonstrated a significantly higher rate of 30-day mortality (0.6% vs 0%; P = .03) and major adverse cardiac events (5.8% vs 0.43%; P < .0001) without any differences seen in reintervention or 30-day type I or type II endoleaks.
    CONCLUSIONS: This systematic review suggests that polyester grafts are strongly associated with PIS compared with PTFE. Interestingly, this report is suggestive of an association between 30-day mortality and major adverse cardiac events and PIS. Given these clinical sequelae, consideration for use of PTFE over polyester grafts to reduce the incidence of PIS may be a simple step to improve overall outcome. Further, exploration of the relationship between inflammatory mediators associated with PIS and mortality and cardiac complications may engender deeper understanding of risks, leading to eventual mitigation of harm for patients experiencing PIS.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Meta-Analysis
    目的:比较开窗式胸主动脉腔内修复术(F-TEVAR)和烟囱式胸主动脉腔内修复术(CH-EVAR)治疗主动脉疾病的技术和临床效果。
    方法:PubMed,系统搜索Embase和Cochrane数据库,以确定2000年至2022年间发表的使用烟囱或开窗技术管理胸主动脉病变的研究。个别研究至少提供了以下基本结果之一:技术成功,立即和后续I型内漏,30天和主动脉相关死亡率,脑事件和主动脉上分支通畅。
    结果:包括24个烟囱(1106名患者)和21个开窗技术研究(1040名患者)。研究范围包括各种胸主动脉疾病,如胸主动脉夹层,胸主动脉瘤,胸主动脉溃疡,和其他胸主动脉疾病。技术成功被定义为处理影响主动脉的主要疾病,没有任何并发症。与烟囱组相比,开窗组的技术成功率更高(98.0%vs.95.8%p<0.001),在烟囱技术组中,立即或随访期间的I型内漏率较高(9.3%vs.1.3%p<0.001,4.0%与0.0%p<0.001)。烟囱技术组比开窗技术组有更高的30天死亡率和主动脉相关死亡率(2.1%vs.0.3%p<0.001,0.4%与0.0%p<0.001)。两组的脑事件和主动脉上分支通畅率相同(2.2%vs.1.1%p=0.116,98.2%与99.4%p=0.094)。烟囱技术组的手术时间更长(110.0minvs.90.8分钟p<0.001)。两组透视时间相同(34.0minvs.33.4分钟p=0.614)。
    结论:该发现表明,烟囱和开窗技术在主动脉上分支重建中都有效。然而,开窗技术作为一种介入策略显示出潜在的优越性,因为它表明1型内漏的发生率较低,30天死亡率,TEVAR术后主动脉相关死亡。
    OBJECTIVE: To compare the technical and clinical outcomes of fenestrated thoracic endovascular aortic repair (F-TEVAR) and chimney thoracic endovascular aortic repair (CH-EVAR) of aortic disease.
    METHODS: PubMed, Embase and Cochrane databases were systematically searched to identify studies on the management of thoracic aortic pathologies using chimney or fenestrated techniques published between 2000 and 2022. Individual studies provided at least one of the following essential outcomes: technical success, immediate and follow-up type I endoleak, 30-day and aorta-related mortality, cerebral events and supra-aortic branch patency.
    RESULTS: 24 chimney (1106 patients) and 21 fenestrated technique studies (1040 patients) were included. The scope of the study encompassed various thoracic aortic conditions, such as thoracic aortic dissection, thoracic aortic aneurysm, thoracic aortic ulcer, and other thoracic aortic diseases. Technical success was defined as the handling of the principal ailment affecting the aorta, devoid of any instances of complications. The technical success rates were higher in fenestrated group compared with chimney group (98.0% vs. 95.8% p < 0.001), and the rate of type I endoleak either immediately or during follow-up was higher in the chimney technique group (9.3% vs. 1.3% p < 0.001, 4.0% vs. 0.0% p < 0.001). The chimney technique group had higher 30-day mortality and aorta-related mortality than those in the fenestrated technique group (2.1% vs. 0.3% p < 0.001, 0.4% vs. 0.0% p < 0.001). Morbidity rates of cerebral events and supra-aortic branch patency were same in both groups (2.2% vs. 1.1% p = 0.116, 98.2% vs. 99.4% p = 0.094). The chimney technique group had longer operative time (110.0 min vs. 90.8 min p < 0.001). Two groups had same fluoroscopy time (34.0 min vs. 33.4 min p = 0.614).
    CONCLUSIONS: The finding suggest that both the chimney and fenestrated techniques are efficacious in supra-aortic branch reconstruction. However, the fenestrated technique exhibits potential superiority as an interventional strategy, as it demonstrates a lower incidence of type 1 Endoleak, 30-day mortality, and aorta-related death following TEVAR.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    提供关于使用内分支内置假体(bTEVAR)治疗主动脉弓病变的胸血管内弓修复的当代结果的描述性概述。
    根据系统评价和荟萃分析的首选报告项目进行了全面的文献检索。从1999年1月至2022年7月,使用预定义的搜索词来询问PubMed和OVIDMedline数据库。患者特征,治疗指征,程序数据,死亡率,术后并发症,评估随访期间的再干预率。
    包括19篇文章,总共包括618名接受bTEVAR的患者,其中大多数是双支链的(63.9%,n=395)。治疗的主要指征是继发于慢性主动脉夹层的动脉瘤(38.8%,n=240/618),平均最大直径为58.3±11.4mm。合并平均技术成功率为97.4±4.4%(95%置信区间[CI]=95.1%-99.5%);2例和3例患者需要转换为烟囱技术和开放修复,分别。在合并的早期并发症发生率中,术后卒中最高(10.5%;95%CI=6.8%-14.3%).30天和院内死亡率为5.5%(95%CI=2.6%-9.7%)。40例患者(6.5%;95%CI=2.5%-9.5%)需要早期再干预。在平均20.7±13.5个月的随访中,死亡率为18.2%(n=108/593;95%CI=8.6%-20.6%),其中12例(11.1%)与主动脉相关.合并晚期再干预率为9.6%(95%CI=4.8%-14.3%)。人口统计学和结果的比较发现,单bTEVAR和双bTEVAR之间没有显着差异。
    尽管存在陡峭的学习曲线,但对于主动脉弓病变,分支胸血管内修复术是一种有希望的方法,具有很高的技术成功率。然而,当代结局反映了术后卒中仍然是主要问题.需要进一步的经验和长期随访才能充分阐明bTEVAR在高危患者主动脉病变管理中的安全性和耐用性。
    结论:本系统综述总结了采用不同内部分支支架的胸主动脉腔内修复术治疗主动脉弓病变的当代结果。来自618例患者的19项研究的汇总结果证明了较高的技术成功率和可接受的死亡率。然而,术后卒中仍然是主要问题.需要长期随访以评估其耐久性。
    UNASSIGNED: To provide a descriptive overview on the contemporary outcomes of thoracic endovascular arch repair with inner branched endoprosthesis (bTEVAR) for the treatment of aortic arch pathologies.
    UNASSIGNED: A comprehensive literature search was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Pre-defined search terms were used to interrogate PubMed and OVID Medline databases from January 1999 to July 2022. Patient characteristics, indication for treatment, procedural data, mortality rates, postoperative complications, and reintervention rate during follow-up were evaluated.
    UNASSIGNED: Nineteen articles were included, encompassing a total of 618 patients who received bTEVAR, most of which were double-branched (63.9%, n=395). The main indication for treatment was aneurysm secondary to chronic aortic dissection (38.8%, n=240/618) with a mean maximum diameter of 58.3±11.4 mm. Pooled mean technical success rate was 97.4±4.4% (95% confidence interval [CI]=95.1%-99.5%); 2 and 3 patients required conversion to chimney technique and open repair, respectively. Among the pooled rates of early complications, postoperative stroke was the highest (10.5%; 95% CI=6.8%-14.3%). Thirty-day and in-hospital mortality rate was 5.5% (95% CI=2.6%-9.7%). Forty patients (6.5%; 95% CI=2.5%-9.5%) required early reintervention. During a mean follow-up of 20.7±13.5 months, the mortality rate was 18.2% (n=108/593; 95% CI=8.6%-20.6%) where 12 (11.1%) were aortic-related. Pooled late reintervention rate was 9.6% (95% CI=4.8%-14.3%). Comparison of demographics and outcomes found no significant difference between single and double bTEVAR.
    UNASSIGNED: Branched thoracic endovascular aortic repair is a promising approach for aortic arch pathologies with a high technical success rate despite a steep learning curve. However, contemporary outcomes reflect that postoperative stroke remains the predominant concern. Further experience and long-term follow-up are required to sufficiently elucidate the safety and durability of bTEVAR in the management of aortic pathologies for high-risk patients.
    CONCLUSIONS: This systematic review summarized the contemporary outcomes of thoracic endovascular aortic repair with different inner branched stent-grafts for the management of aortic arch pathologies. Pooled results from nineteen studies with 618 patients demonstrated a high technical success rate and an acceptable mortality rate. However, postoperative stroke remains the major concern. Long-term follow-up is needed to evaluate its durability.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Meta-Analysis
    目的:评估血管内动脉瘤修复(EVAR)失败后半转换(开放转换和移植物保存)后的结果。主要结果是30天死亡率和半转换失败。次要结果是30天的主要全身并发症,内漏复发,再干预,总生存率。
    方法:审查遵循系统审查和荟萃分析(PRISMA)指南的首选报告项目。该方案在PROSPERO(CRD42023421153)上进行了前瞻性注册。所有报告失败的EVAR半转换结果的研究均有资格纳入。使用非随机研究方法学指数(MINORS)工具进行质量评估。考虑到主要结局中的频繁零事件率,使用双arcsine-Tukey转换对比例进行了随机效应元回归。用I2统计量评估异质性。
    结果:8项研究在全文筛选后纳入综述。196例患者从EVAR平均47.4个月开始进行半转换,68.9%的选修设置。转换时的平均年龄为78.1岁,主要适应症是孤立的内漏II型(占病例的70.1%)。在92.3%的半转换中不需要主动脉夹紧,96.1%的病例打开了主动脉囊,在93.3%的病例中,对一条或多条罪犯动脉进行了结扎/缝合,29.2%的人进行了主动脉颈带术。手术后30天,合并死亡率和主要全身并发症发生率分别为5.3%(I2:24.9%)和13.4%(I2:54.3%).在后续行动中,内漏在12.6%的半转换后复发(I2:83.2%),再干预率为7%(I2:50.1%);半转换失败率为5.5%(I2:54.1%),总生存率为84.6%(I2:33.3%)。
    结论:半转换具有可接受的30天死亡率,但是早期和中期并发症的风险,再干预,破裂和感染是不可忽视的。对于主动脉交叉钳夹不理想的患者,此程序可能是完全或部分移植外植体的替代方法。
    OBJECTIVE: The aim of this study was to evaluate the outcomes after semi-conversion (open conversion with graft preservation) after failed endovascular aneurysm repair (EVAR). The primary outcomes were 30-day mortality and semi-conversion failure. Secondary outcomes were 30-day major systemic complications, endoleak recurrence, reinterventions, and overall survival.
    METHODS: The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol was prospectively registered on PROSPERO (CRD42023421153). All studies reporting the outcomes of semi-conversions for failed EVAR were eligible for inclusion. Quality assessment was performed using the Methodological Index for Non-Randomized Studies (MINORS) tool. A random effects meta-regression of proportions was conducted using the double arcsine-Tukey transformation, given the frequent zero event rate in the primary outcome. Heterogeneity was assessed with the I2 statistic.
    RESULTS: Eight studies were included in the review after full text screening. A total of 196 patients underwent semi-conversion at a mean time from EVAR of 47.4 months, 68.9% in an elective setting. Mean age at conversion was 78.1 years, and the main indication was isolated endoleak type II (70.1% of cases). Aortic clamping was not necessary in 92.3% of semi-conversions; the aortic sac was opened in 96.1% of cases; in 93.3% of cases, ligation/suture of one or more culprit arteries were performed; and aortic neck banding was executed in 29.2%. At 30 days from surgery, the pooled mortality and the major systemic complications rates were 5.3% (I2 = 24.9%) and 13.4% (I2 = 54.3%), respectively. At follow-up, endoleak recurred after 12.6% semi-conversions (I2 = 83.2%), and the rate of reinterventions was 7% (I2 = 50.1%); the semi-conversion failure rate was 5.5% (I2 = 54.1%), and the overall survival was 84.6% (I2 = 33.3%).
    CONCLUSIONS: Semi-conversions have acceptable 30-day mortality rates, but the early and mid-term risks of complications, reinterventions, ruptures, and infections are not negligible. This procedure might be an alternative to complete or partial graft explant in patients whom aortic cross-clamping is not ideal.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Review
    血管内动脉瘤修复术(EVAR)是腹主动脉瘤的主要治疗策略,占美国所有维修的80%。内漏无处不在,影响到30%接受EVAR治疗的患者,可能导致囊扩大和破裂风险增加。EVAR患者的护理需要多学科团队的长期监测。因此,医生应该熟悉内漏管理的基本原理,以达到最佳效果,包括及时转诊进行补救或在需要时提供咨询和保证。
    在PubMed和Cochrane数据库中搜索了2002年1月至2022年12月之间以英文发表的文章,解决流行病学问题,诊断,和EVAR后内漏的管理。内漏可以在术中或几年后检测到,强制终身监控。I型和III型破裂的风险最高(2年为7.5%,1年为8.9%,分别),并应在确定时进行处理。根据目前的指南,当与动脉瘤囊生长大于5mm相关的其他类型的内漏时,应考虑干预。II型内漏是最常见的,占所有内漏的50%。高达90%的II型内漏自发消退或与囊扩大无关。只需要观察。虽然破裂的风险小于1%,需要重新干预的案件具有挑战性。尽管进行了血管内治疗,但复发仍然很常见,并且破裂可以在没有囊生长的证据的情况下发生。IV型内漏和内阻并不常见,通常是良性的,首先应该被观察。
    Endoleak管理取决于囊膨胀的类型和存在。I型和III型内漏需要干预。对于囊明显扩张的患者,应观察并选择性治疗II型内漏。由于内漏可以在EVAR之后的任何时间出现,建议每5年由有经验的实验室进行至少1次对比增强的CT血管造影或双工超声检查.
    Endovascular aneurysm repair (EVAR) is the dominant treatment strategy for abdominal aortic aneurysms, encompassing 80% of all repairs in the United States. Endoleaks are ubiquitous and affect 30% of patients treated by EVAR, potentially leading to sac enlargement and increased risk of rupture. The care of EVAR patients requires long-term surveillance by a multidisciplinary team. Accordingly, physicians should be familiar with the fundamentals of endoleak management to achieve optimal outcomes, including timely referral for remediation or providing counseling and reassurance when needed.
    PubMed and the Cochrane database were searched for articles published between January 2002 and December 2022 in English, addressing epidemiology, diagnosis, and management of endoleaks after EVAR. Endoleaks can be detected intraoperatively or years later, making lifelong surveillance mandatory. Type I and III have the highest risk of rupture (7.5% at 2 years and 8.9% at 1 year, respectively) and should be treated when identified. Intervention should be considered for other types of endoleak when associated with aneurysm sac growth larger than 5 mm based on current guidelines. Type II endoleaks are the most common, accounting for 50% of all endoleaks. Up to 90% of type II endoleaks resolve spontaneously or are not associated with sac enlargement, requiring only observation. Although the risk of rupture is less than 1%, cases that require reintervention are challenging. Recurrence is common despite endovascular treatment, and rupture can occur without evidence of sac growth. Type IV endoleaks and endotension are uncommon, are typically benign, and primarily should be observed.
    Endoleak management depends on the type and presence of sac expansion. Type I and III endoleaks require intervention. Type II endoleaks should be observed and treated selectively in patients with significant sac expansion. Since endoleaks can appear any time after EVAR, at least 1 contrast-enhanced computed tomographic angiogram or duplex ultrasound by an experienced laboratory is recommended every 5 years.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号